Cognition Therapeutics (CGTX) Price & Analysis

Compare

580 Followers

CGTX Stock Chart & Stats

$1.74

-$0.03(-3.56%)

At close: Jan 08 4:00 PM EST

$1.74

-$0.03(-3.56%)

Day’s Range― - ―

52-Week Range$0.22 - $3.83

Previous CloseN/A

Volume950.02K

Average Volume (3M)2.91M

Market Cap

$138.51M

Enterprise Value$8.64M

Total Cash (Recent Filing)$39.82M

Total Debt (Recent Filing)$380.00K

Price to Earnings (P/E)―

Beta2.04

Next Earnings

Apr 01, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding88,223,885

10 Day Avg. Volume2,171,776

30 Day Avg. Volume2,911,286

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.49

Price to Sales (P/S)0.00

P/FCF Ratio-0.98

Enterprise Value/Market Cap0.06

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-141.68

Enterprise Value/Ebitda-0.31

Forecast

1Y Price Target

$3.00

Price Target Upside72.41% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsCognition Therapeutics has successfully completed enrollment for the Phase 2 'START' study, reaching the target of 540 participants.

Collaborations And FundingThe START study is conducted with collaboration and funding from reputable organizations, including the Alzheimer's Clinical Trials Consortium and the National Institute of Aging.

Treatment AdvancementsZervimesine has shown substantial promise in treating dementia with Lewy bodies, demonstrating a clinically meaningful impact on patients in various measures.

Bears Say

Cognition Therapeutics News

Cognition Therapeutics price target raisd to $3 from $2 at B. Riley

B. Riley raised the firm’s price target on Cognition Therapeutics (CGTX) to $3 from $2 and keeps a...

9d ago

CGTX

Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine

Cognition Therapeutics (CGTX) announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled...

17d ago

CGTX

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

“The $30 million registered direct offering enables us to begin preparations for the next stage of development for...

24d ago

CGTX

Optimistic Buy Rating for Cognition Therapeutics Amid Promising Developments in Alzheimer’s and Dementia Treatment

Cognition Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

21d ago

CGTX

Cognition Therapeutics Advances Alzheimer’s Drug Development

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q3 earnings. Here is a breakdown of the information...

24d ago

CGTX

Cognition Therapeutics Advances Zervimesine to Phase 3 Trials

Cognition Therapeutics ( ($CGTX) ) has shared an update. Cognition Therapeutics is advancing its lead product candidate, zervimesine,...

3M ago

CGTX

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

Cognition Therapeutics (CGTX) announced that the Phase 2 ‘START’ Study has reached the 75% enrollment mark. The START...

3M ago

CGTX

Cognition Therapeutics Announces $30.1M Direct Offering

Cognition Therapeutics ( ($CGTX) ) has issued an update. On August 27, 2025, Cognition Therapeutics, Inc. announced it...

3M ago

CGTX

Cognition Therapeutics announces $30M registered direct offering of common stock

Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the...

3M ago

CGTX

Cognition Therapeutics Regains Nasdaq Compliance

Cognition Therapeutics ( ($CGTX) ) has issued an update. Cognition Therapeutics, Inc. received a deficiency letter from Nasdaq...

3M ago

CGTX

Cognition Therapeutics regains compliance with Nasdaq

Cognition Therapeutics (CGTX) was notified by Nasdaq that the company has regained compliance with the exchange’s continued listing...

3M ago

CGTX

Cognition Therapeutics Reports Q2 2025 Financial Results

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

CGTX

Cognition Therapeutics confirms aligment with FDA on path for zervimesine

Cognition Therapeutics (CGTX) received final minutes from the FDA pertaining to the end-of-Phase 2 meeting that was conducted...

4M ago

CGTX

Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics and keeping the price target...

4M ago

CGTX

CGTX FAQ

What was Cognition Therapeutics’s price range in the past 12 months?

Cognition Therapeutics lowest stock price was $0.22 and its highest was $3.83 in the past 12 months.

What is Cognition Therapeutics’s market cap?

Cognition Therapeutics’s market cap is $138.51M.

When is Cognition Therapeutics’s upcoming earnings report date?

Cognition Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 121 days.

How were Cognition Therapeutics’s earnings last quarter?

Cognition Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.03.

Is Cognition Therapeutics overvalued?

According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cognition Therapeutics pay dividends?

Cognition Therapeutics does not currently pay dividends.

What is Cognition Therapeutics’s EPS estimate?

Cognition Therapeutics’s EPS estimate is -0.08.

How many shares outstanding does Cognition Therapeutics have?

Cognition Therapeutics has 88,223,885 shares outstanding.

What happened to Cognition Therapeutics’s price movement after its last earnings report?

Cognition Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -1.775%.

Which hedge fund is a major shareholder of Cognition Therapeutics?

Currently, no hedge funds are holding shares in CGTX

Cognition Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-109.73%

Trailing 12-Months

Asset Growth

-42.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cognition Therapeutics

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics (CGTX) Earnings & Revenues

Historic Earnings Reports

CGTX Stock 12 Month Forecast

Average Price Target

$3.00

▲(72.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.79,1.883076923076923,1.9761538461538461,2.0692307692307694,2.1623076923076923,2.2553846153846155,2.3484615384615384,2.4415384615384617,2.5346153846153845,2.6276923076923078,2.7207692307692306,2.813846153846154,2.9069230769230767,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.79,1.883076923076923,1.9761538461538461,2.0692307692307694,2.1623076923076923,2.2553846153846155,2.3484615384615384,2.4415384615384617,2.5346153846153845,2.6276923076923078,2.7207692307692306,2.813846153846154,2.9069230769230767,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.79,1.883076923076923,1.9761538461538461,2.0692307692307694,2.1623076923076923,2.2553846153846155,2.3484615384615384,2.4415384615384617,2.5346153846153845,2.6276923076923078,2.7207692307692306,2.813846153846154,2.9069230769230767,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >